^
Association details:
| Biomarker: | EGFR mutation + CREBBP mutation |
|---|---|
| Cancer: | Lung Non-Small Cell Squamous Cancer |
| Drug Class: | EGFR inhibitor + Tyrosine kinase inhibitor |
| Direction: | Resistant |
Evidence:
Source:
Title:
1215P - EGFR-mutated squamous cell lung cancer and its association with outcomes
Published date:
09/13/2021
Excerpt:
Among the patients with EGFR mutations, shorter progression-free survival (PFS) was observed in SCC compared to adenocarcinoma (4.6 vs. 11.0 months, P<0.001)…Further exploration of EGFR-mutant SCC revealed that mutations in CREBBP (P=0.005), ZNF217 (P=0.016), and the Wnt (P=0.027) pathway were negatively associated with PFS.
